4.23
-0.55 (-11.43%)
| Previous Close | 4.77 |
| Open | 4.73 |
| Volume | 1,264,114 |
| Avg. Volume (3M) | 1,215,596 |
| Market Cap | 294,216,320 |
| Price / Sales | 5.45 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2025 - 12 May 2025 |
| Operating Margin (TTM) | -200.30% |
| Diluted EPS (TTM) | -5.29 |
| Quarterly Revenue Growth (YOY) | 4,249.60% |
| Current Ratio (MRQ) | 4.20 |
| Operating Cash Flow (TTM) | -266.77 M |
| Levered Free Cash Flow (TTM) | -203.85 M |
| Return on Assets (TTM) | -43.78% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Phathom Pharmaceuticals, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | -1.5 |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | -0.10 |
|
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 3.80% |
| % Held by Institutions | 97.00% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Checkpoint Capital L.P. | 31 Dec 2024 | 2,274,157 |
| Catalys Pacific, Llc | 31 Dec 2024 | 1,167,114 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 28.00 (HC Wainwright & Co., 562.72%) | Buy |
| 28.00 (Needham, 562.72%) | Buy | |
| Median | 28.00 (562.72%) | |
| Low | 10.00 (Goldman Sachs, 136.69%) | Hold |
| Average | 22.00 (420.71%) | |
| Total | 2 Buy, 1 Hold | |
| Avg. Price @ Call | 4.62 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Goldman Sachs | 17 Apr 2025 | 10.00 (136.69%) | Hold | 4.38 |
| 10 Mar 2025 | 12.00 (184.02%) | Hold | 4.40 | |
| Needham | 09 Apr 2025 | 28.00 (562.72%) | Buy | 4.43 |
| 02 Apr 2025 | 28.00 (562.72%) | Buy | 5.49 | |
| HC Wainwright & Co. | 07 Mar 2025 | 28.00 (562.72%) | Buy | 5.06 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| HENDERSON MOLLY | - | 4.87 | -3,678 | -17,912 |
| Aggregate Net Quantity | -3,678 | |||
| Aggregate Net Value ($) | -17,912 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 4.87 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| HENDERSON MOLLY | Officer | 07 Apr 2025 | Sell (-) | 3,678 | 4.87 | 17,912 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |